1689-P: Assessments of Alternative C-Peptide (C-P) Endpoints for New-Onset Type 1 Diabetes (T1D) Clinical Trials

The mean 2-hour MMTT AUC C-P at 12 months of follow-up has been the primary endpoint for all TrialNet clinical trials of individuals newly diagnosed with T1D. However, it is possible that other measures of C-P responsiveness from MMTTs could provide useful efficacy information for such trials. Thus, we assessed other C-P measures as potential endpoints by substituting them in place of the AUC C-P in completed trials that showed effects of...